J Korean Med Sci.  2007 Aug;22(4):677-681. 10.3346/jkms.2007.22.4.677.

Drug Resistance Rates of Mycobacterium tuberculosis at a Private Referral Center in Korea

• Choi JC
• Lim SY
• Suh GY
• Chung MP
• Kim H
• Kwon OJ
• Lee NY
• Park YK
• Bai GH
• Koh WJ

• KMID: 1127086
• DOI: http://doi.org/10.3346/jkms.2007.22.4.677

Abstract

The goals of this study were to identify first-line drug resistance in new and previously treated tuberculosis (TB) cases and to determine risk factors for multidrugresistant TB (MDR-TB) at a private referral center in Korea. All patients with cultureconfirmed pulmonary TB over a 2-yr period between July 2002 and June 2004 were prospectively included in this study. In total, 637 patients were included; 512 (80.4%) were new cases, and 125 (19.6%) were previously treated cases. Resistance to at least one first-line drug was identified in 11.7% of new cases and 41.6% of previously treated cases. MDR-TB was detected in 3.9% of new cases and 27.2% of previously treated cases. The proportion of extensively drug-resistant TB among MDR-TB patients was 16.7% (9/54). Factors associated with MDR-TB included age under 45 yr, previous TB treatment, and the presence of cavitation on chest radiography. Rates of first-line drug resistance are high, particularly in previously treated patients, in the private sector in Korea. This underscores the need for an improved control program, coupled with early diagnosis of MDR-TB, to reduce the spread and development of resistance.

Keyword

Mycobacterium tuberculosis; Korea; Drug Resistance; Isoniazid; Rifampin

MeSH Terms

Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Antitubercular Agents/pharmacology/therapeutic use
Drug Resistance, Bacterial
Drug Resistance, Multiple
Female
Hospitals/statistics & numerical data
Humans
Korea/epidemiology
Logistic Models
Male
Middle Aged
Mycobacterium tuberculosis/*drug effects
Prospective Studies
Referral and Consultation
Risk Factors
Tuberculosis, Multidrug-Resistant/*drug therapy/epidemiology/microbiology
Tuberculosis, Pulmonary/*drug therapy/microbiology

Reference

1. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baez J, Kochi A, Dye C, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA. 2000. 283:2537–2545.

2. Colebunders R, Apers L, Shamputa IC. Treatment of multidrug-resistant tuberculosis. Lancet. 2004. 363:1240.

3. Timperi R, Han LL, Sloutsky A, Becerra MC, Nardell EA, Salazar JJ, Smith-Fawzi MC. Drug resistance profiles of Mycobacterium tuberculosis isolates: five years' experience and insight into treatment strategies for MDR-TB in Lima, Peru. Int J Tuberc Lung Dis. 2005. 9:175–180.

4. Ferrara G, Richeldi L, Bugiani M, Cirillo D, Besozzi G, Nutini S, Casali L, Fiorentini F, Codecasa LR, Migliori GB. Management of multidrug-resistant tuberculosis in Italy. Int J Tuberc Lung Dis. 2005. 9:507–513.

5. Torun T, Gungor G, Ozmen I, Bolukbasi Y, Maden E, Bicakci B, Atac G, Sevim T, Tahaoglu K. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2005. 9:1373–1377.

6. Kang YA, Choi YJ, Cho YJ, Lee SM, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ. Cost of treatment for multidrug-resistant tuberculosis in South Korea. Respirology. 2006. 11:793–798.

7. Korean Center for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea (2005.1-2005.12). 2006.

8. Seung KJ, Bai GH, Kim SJ, Lew WJ, Park SK, Kim JY. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis. 2003. 7:912–919.

9. Kim SJ, Bai GH, Hong YP. Drug-resistant tuberculosis in Korea, 1994. Int J Tuberc Lung Dis. 1997. 1:302–308.

10. Pablos-Mendez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998. 338:1641–1649.

11. Espinal MA, Laszlo A, Simonsen L, Boulahbal F, Kim SJ, Reniero A, Hoffner S, Rieder HL, Binkin N, Dye C, Williams R, Raviglione MC. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 2001. 344:1294–1303.

12. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, Lee JK, Kim SJ. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

13. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000. 161:1376–1395.

14. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 2003.

15. World Health Organization. Report of the meeting of the WHO Global Task Force on XDR-TB. 2006.

16. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis. 1998. 2:27–36.

17. Kim JH, Kim JH, Jang TW, Jung MH. Drug-resistant pulmonary tuberculosis in Kosin Medical Center. Tuber Respir Dis. 1995. 42:831–837.

18. Kim SY, Jeong SS, Kim KW, Shin KS, Park SG, Kim AK, Cho HJ, Kim JO. Drug-resistant pulmonary tuberculosis in a tertiary referral hospital in Korea. Korean J Intern Med. 1999. 14:27–31.

19. Lee JH, Chang JH. Drug-resistant tuberculosis in a tertiary referral teaching hospital of Korea. Korean J Intern Med. 2001. 16:173–179.

20. Kim DK, Kim MO, Kim TH, Sohn JW, Yoon HJ, Shin DH, Park SS. The prevalence and risk factors of drug resistance pulmonary tuberculosis investigated at one university hospital in Seoul. Tuber Respir Dis. 2005. 58:243–247.

21. Centers for Disease Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs--worldwide, 2000-2004. MMWR Morb Mortal Wkly Rep. 2006. 55:301–305.

22. Arevalo M, Solera J, Cebrian D, Bartolome J, Robles P. Risk factors associated with drug-resistant Mycobacterium tuberculosis in Castilla-la-Mancha (Spain). Eur Respir J. 1996. 9:274–278.

23. Ruddy M, Balabanova Y, Graham C, Fedorin I, Malomanova N, Elisarova E, Kuznetznov S, Gusarova G, Zakharova S, Melentyev A, Krukova E, Golishevskaya V, Erokhin V, Dorozhkova I, Drobniewski F. Rates of drug resistance and risk factor analysis in civilian and prison patients with tuberculosis in Samara Region, Russia. Thorax. 2005. 60:130–135.

24. Faustini A, Hall AJ, Perucci CA. Risk factors for multi-drug resistant tuberculosis in Europe: a systematic review. Thorax. 2006. 61:158–163.

25. Djuretic T, Herbert J, Drobniewski F, Yates M, Smith EG, Magee JG, Williams R, Flanagan P, Watt B, Rayner A, Crowe M, Chadwick MV, Middleton AM, Watson JM. Antibiotic resistant tuberculosis in the United Kingdom: 1993-1999. Thorax. 2002. 57:477–482.

26. Kordy FN, Al-Thawadi S, Alrajhi AA. Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia. Int J Tuberc Lung Dis. 2004. 8:1007–1011.

27. Harrow EM, Rangel JM, Arriega JM, Cohen I, Regil Ruiz MI, De-Riemer K, Small PM. Epidemiology and clinical consequences of drug-resistant tuberculosis in a Guatemalan hospital. Chest. 1998. 113:1452–1458.

28. Sharma SK, Turaga KK, Balamurugan A, Saha PK, Pandey RM, Jain NK, Katoch VM, Mehra NK. Clinical and genetic risk factors for the development of multi-drug resistant tuberculosis in non-HIV infected patients at a tertiary care center in India: a case-control study. Infect Genet Evol. 2003. 3:183–188.

29. Espinal MA, Laserson K, Camacho M, Fusheng Z, Kim SJ, Tlali RE, Smith I, Suarez P, Antunes ML, George AG, Martin-Casabona N, Simelane P, Weyer K, Binkin N, Raviglione MC. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis. 2001. 5:887–893.